BRPI0400869B8 - novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases - Google Patents

novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases

Info

Publication number
BRPI0400869B8
BRPI0400869B8 BRPI0400869A BRPI0400869A BRPI0400869B8 BR PI0400869 B8 BRPI0400869 B8 BR PI0400869B8 BR PI0400869 A BRPI0400869 A BR PI0400869A BR PI0400869 A BRPI0400869 A BR PI0400869A BR PI0400869 B8 BRPI0400869 B8 BR PI0400869B8
Authority
BR
Brazil
Prior art keywords
adenosine kinase
compounds
adenosine
anilinoquinazolines
compounds derived
Prior art date
Application number
BRPI0400869A
Other languages
English (en)
Inventor
Gomes Franchini Kleber
José Abdalla Saad Mário
Rittner Neto Roberto
Miguel Marin Rodrigo
Aparecida Rocco Silvana
Original Assignee
Univ Estadual Campinas Unicamp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Estadual Campinas Unicamp filed Critical Univ Estadual Campinas Unicamp
Priority to BRPI0400869A priority Critical patent/BRPI0400869B8/pt
Priority to MXPA06009987A priority patent/MXPA06009987A/es
Priority to CA2558501A priority patent/CA2558501C/en
Priority to CN2004800427393A priority patent/CN1938285B/zh
Priority to PCT/BR2004/000196 priority patent/WO2005085213A1/en
Priority to KR1020067019959A priority patent/KR101089493B1/ko
Priority to EP04761556A priority patent/EP1737832B1/en
Publication of BRPI0400869A publication Critical patent/BRPI0400869A/pt
Priority to US11/515,514 priority patent/US8513267B2/en
Publication of BRPI0400869B1 publication Critical patent/BRPI0400869B1/pt
Publication of BRPI0400869B8 publication Critical patent/BRPI0400869B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases". a presente invenção apresenta compostos que são inibidores de adenosinacinases. é proporcionado um processo de proteger tecidos e órgãos como coração, cérebro e rins atingidos por isquemia e tratar insuficiência cardíaca, infarto do miocárdio, arritmias, hipertensão arterial, aterosclerose, re-estenose de artéria coronária após a angioplastia, insuficiência renal crônica, acidente vascular cerebral, doenças inflamatórias crônicas (e.g. artrite reumatóide). também proporcionado é o efeito inibidor de adenosina-cinases de compostos derivados de quinazolinas previamente conhecidos como inibidores reversíveis de tirosina-cinases da família de receptores do fator de crescimento epidérmico (egfr).
BRPI0400869A 2004-02-03 2004-03-02 novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases BRPI0400869B8 (pt)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0400869A BRPI0400869B8 (pt) 2004-03-02 2004-03-02 novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
MXPA06009987A MXPA06009987A (es) 2004-03-02 2004-10-07 Derivados de 4-anilinoquinazolinas con propiedades inhibidoras de adenosina-cinasa.
CA2558501A CA2558501C (en) 2004-03-02 2004-10-07 4-anilinoquinazolines derivatives with adenosine-kinase inhibitory properties
CN2004800427393A CN1938285B (zh) 2004-03-02 2004-10-07 具有腺苷激酶抑制性质的4-苯胺基喹唑啉衍生物
PCT/BR2004/000196 WO2005085213A1 (en) 2004-03-02 2004-10-07 Compounds derived from 4­-anilinequinazolines with adenosine-kiase inhibitor properties
KR1020067019959A KR101089493B1 (ko) 2004-03-02 2004-10-07 아데노신-키나아제 저해 특성을 갖는 4-아닐리노퀴나졸린 유도체
EP04761556A EP1737832B1 (en) 2004-03-02 2004-10-07 4-anilinoquinazoline derivatives with adenosine-kinase inhibitory properties
US11/515,514 US8513267B2 (en) 2004-02-03 2006-09-01 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0400869A BRPI0400869B8 (pt) 2004-03-02 2004-03-02 novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases

Publications (3)

Publication Number Publication Date
BRPI0400869A BRPI0400869A (pt) 2006-03-07
BRPI0400869B1 BRPI0400869B1 (pt) 2018-03-06
BRPI0400869B8 true BRPI0400869B8 (pt) 2021-05-25

Family

ID=36091621

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0400869A BRPI0400869B8 (pt) 2004-02-03 2004-03-02 novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases

Country Status (8)

Country Link
US (1) US8513267B2 (pt)
EP (1) EP1737832B1 (pt)
KR (1) KR101089493B1 (pt)
CN (1) CN1938285B (pt)
BR (1) BRPI0400869B8 (pt)
CA (1) CA2558501C (pt)
MX (1) MXPA06009987A (pt)
WO (1) WO2005085213A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0400869B8 (pt) 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
CN106632271A (zh) * 2016-11-18 2017-05-10 河南师范大学 具有抗肿瘤活性的厄洛替尼衍生物及其制备方法和应用
CN107245072A (zh) * 2016-11-18 2017-10-13 河南师范大学 一种厄洛替尼‑1,2,3‑三氮唑类化合物的制备方法
CN108310369B (zh) * 2018-03-27 2021-07-16 复旦大学附属中山医院 一种用于经皮冠状动脉介入治疗的给药系统

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5763596A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5721356A (en) * 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5763597A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
AU665184B2 (en) 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
KR20010089284A (ko) * 1998-10-01 2001-09-29 다비드 에 질레스 화합물
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
KR20020032608A (ko) * 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 화합물 및 이를 함유하는 제약 조성물
WO2004013091A2 (en) * 2002-08-01 2004-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
BRPI0400869B8 (pt) 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases

Also Published As

Publication number Publication date
BRPI0400869B1 (pt) 2018-03-06
KR20070008605A (ko) 2007-01-17
US20070060600A1 (en) 2007-03-15
EP1737832A1 (en) 2007-01-03
WO2005085213A1 (en) 2005-09-15
US8513267B2 (en) 2013-08-20
BRPI0400869A (pt) 2006-03-07
CA2558501A1 (en) 2005-09-15
CN1938285B (zh) 2011-10-05
MXPA06009987A (es) 2007-05-11
CN1938285A (zh) 2007-03-28
CA2558501C (en) 2011-02-22
KR101089493B1 (ko) 2011-12-02
EP1737832B1 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
Wissner et al. Synthesis and structure− activity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)
WO2010077680A3 (en) Compositions of protein receptor tyrosine kinase inhibitors
CY1126044T1 (el) Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων
MX2011006503A (es) Derivados de pirazina utiles como inhibidores de la cinasa de atr.
BR122020005540B8 (pt) processos para preparar composições de inibidores jak
MX2011004953A (es) Compuestos utiles como inhibidores de cinasa atr.
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
BR0312940A (pt) Inibidores de quinases
NZ587589A (en) Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
DE60002714D1 (de) Substituierte azaoxindolederivate
MA31167B1 (fr) Inhibiteurs de l'activite de akt
WO2011143423A3 (en) Compounds useful as inhibitors of atr kinase
ECSP10010429A (es) Derivados bicíclicos heterocíclicos o espirobicíclicos heterocíclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparación y usos de los mismos
HRP20130797T1 (en) Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
WO2008078100A3 (en) Tricyclic amine derivatives as protein tyrosine kinase inhibitors
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
UY27181A1 (es) Derivados de xantina, su preparación y su empleo como medicamentos.
DE60037905D1 (de) Pyrazin-basierte hemmer der glycogen-synthase-kinase 3
CR8148A (es) Derivados del indazolil (indolil) maleimida sustituidos como inhibidores de la cinasa
ATE477251T1 (de) Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
WO2002076976A3 (en) Rho-kinase inhibitors
BR0311619A (pt) Derivados de pirazol como inibidores de cinase p38
WO2008148867A3 (en) Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of janus kinases
MX2008011258A (es) Derivados de quinazolina como inhibidores de fosfodiesterasa 10.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 46 (QUARENTA E SEIS) DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF